RE:RE:RE:RE:RE:RE:RE:CG Oncology phase 3 results impossible for TLT to beat?For Theralase to get a BTD for Ruvidar PDT it needs to demonstrate a substantial improvement over an available therapy.
CG0070 is not an available therapy either as a standalone or as a combo treatment with Keytruda, It does not have FDA approval.
Therefore it has nothing to do with whether or not Ruvidar PDT gets a BTD or not. Ruvidar PDT needs to show a substantial improvennt over existing approved treatments - i,e. Keytruda and Adstiladrin.
I think you underestimate the significance of having to constantly retreat patients so that they maintain a response.
It means the cancer keeps coming back! With Ruvdar PDT it looks very much like 39% of optimized patients (so far) have been completely cured of their cancer after only 2 treatments.
It means the cancer does not come back! You can pretty up the data any way you like but urologists will not be fooled. If they care about their patients I'm sure they will prefer to send their patients home cured after 6 months rather than condemn them to a lifetime of continual treatments which become less and less effective over time.
Gman620 wrote: Why should TLT get BTD with this out there? Having lots of treatments and working with Keytruda is the exact sweet spot big pharma wants, hence their big money backers.
Hard not to see this as a dagger to TLT. As I've said before, if it has a high success rate, no one, especially patients, cares about number of treatments. That's what pharma wants anyway.